Next Article in Journal
Adherence to and Uptake of Clinical Practice Guidelines: Lessons Learned from a Clinical Practice Guideline on Chemotherapy Concomitant with Radiotherapy in Head-and-Neck Cancer
Previous Article in Journal
Using the Cancer Risk Management Model to Evaluate Colorectal Cancer Screening Options for Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 2
10.3747/co.22.2210
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer

by
L. Manso
1,*,
F. Moreno
2,
R. Márquez
3,
B. Castelo
4,
A. Arcediano
5,
M. Arroyo
6,
A.I. Ballesteros
7,
I. Calvo
8,
M.J. Echarri
9,
S. Enrech
10,
A. Gómez
11,
R. González del Val
12,
E. López–Miranda
13,
M. Martín–Angulo
6,
N. Martínez–Jañez
13,
C. Olier
14 and
P. Zamora
4
1
Hospital Universitario 12 de Octubre, Madrid, Spain
2
Hospital Universitario Clínico San Carlos, Madrid, Spain
3
MD Anderson Cancer Center, Madrid, Spain
4
Hospital Universitario La Paz, Madrid, Spain
5
Hospital General Universitario de Guadalajara, Guadalajara, Mexico
6
Hospital Príncipe de Asturias, Alcalá de Henares, Spain
7
Hospital de la Princesa, Madrid, Spain
8
Centro Integral Oncológico Clara Campal, Madrid, Spain
9
Hospital Universitario Severo Ochoa, Leganés, Spain
10
Hospital Universitario de Getafe, Getafe, Spain
11
Hospital Universitario de Salamanca, Salamanca, Spain
12
Hospital Gregorio Marañón, Madrid, Spain
13
Hospital Ramón y Cajal, Madrid, Spain
14
Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(2), 51-60; https://doi.org/10.3747/co.22.2210
Submission received: 5 January 2015 / Revised: 3 February 2015 / Accepted: 3 March 2015 / Published: 1 April 2015

Abstract

Objective: During clinical practice, it can be challenging, given the lack of response biomarkers, to identify the patients with metastatic breast cancer (mbca) who would benefit most from the addition of bevacizumab to first-line standard chemotherapy. The aim of the present review was to summarize the relevant scientific evidence and to discuss the experience of a group of experts in using bevacizumab to treat mbca. Methods: A panel of 17 Spanish oncology experts met to discuss the literature and their experience in the use of bevacizumab as first-line treatment for mbca. During the meeting, discussions focused on three main issues: the profile of the patients who could benefit most from bevacizumab, the optimal bevacizumab treatment duration, and the safety profile of bevacizumab. Results: The subset of mbca patients who would benefit the most from the addition of bevacizumab to first-line standard chemotherapy are those with clinically defined aggressive disease. Treatment with bevacizumab should be maintained until disease progression or the appearance of unacceptable toxicity. In the mbca setting, the toxicity profile of bevacizumab is well known and can be managed in clinical practice after adequate training. Conclusions: This expert group recommends administering bevacizumab as first-line treatment in patients with clinically aggressive disease.
Keywords: bevacizumab; metastatic breast cancer; clinical practice bevacizumab; metastatic breast cancer; clinical practice

Share and Cite

MDPI and ACS Style

Manso, L.; Moreno, F.; Márquez, R.; Castelo, B.; Arcediano, A.; Arroyo, M.; Ballesteros, A.I.; Calvo, I.; Echarri, M.J.; Enrech, S.; et al. Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer. Curr. Oncol. 2015, 22, 51-60. https://doi.org/10.3747/co.22.2210

AMA Style

Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, et al. Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer. Current Oncology. 2015; 22(2):51-60. https://doi.org/10.3747/co.22.2210

Chicago/Turabian Style

Manso, L., F. Moreno, R. Márquez, B. Castelo, A. Arcediano, M. Arroyo, A.I. Ballesteros, I. Calvo, M.J. Echarri, S. Enrech, and et al. 2015. "Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer" Current Oncology 22, no. 2: 51-60. https://doi.org/10.3747/co.22.2210

APA Style

Manso, L., Moreno, F., Márquez, R., Castelo, B., Arcediano, A., Arroyo, M., Ballesteros, A. I., Calvo, I., Echarri, M. J., Enrech, S., Gómez, A., del Val, R. G., López–Miranda, E., Martín–Angulo, M., Martínez–Jañez, N., Olier, C., & Zamora, P. (2015). Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer. Current Oncology, 22(2), 51-60. https://doi.org/10.3747/co.22.2210

Article Metrics

Back to TopTop